Frequencies of Treg and Th17 Cells in the PB and PF of Women With and Without Endometriosis
. | Control . | Revised ASRM Stage I-II . | Revised ASRM Stage III-IV . |
---|---|---|---|
Peripheral blood: | |||
CD4+CD25+FoxP3+ | |||
Treg cells | 5.5 ± 2.3 | 4.8 ± 2.9 | 5.2 ± 2.5 |
Range in frequency | 2.2–10.9 | 1.0–10.1 | 1.2–10.5 |
CD4+IL-17A+ | |||
Th17 cells | 0.5 ± 0.4 | 0.5 ± 0.4 | 0.3 ± 0.3 |
Range in frequency | 0–1.3 | 0–1.3 | 0–0.9 |
Peritoneal fluid: | |||
CD4+CD25+FoxP3+ | |||
Treg cells | 7.6 ± 2.8 | 6.9 ± 3.3 | 11.4 ± 6.8a |
Range in frequency | 3.2–14.9 | 1.4–11.4 | 2.6–24.5 |
CD4+IL-17A+ | |||
Th17 cells | 0.4 ± 0.3 | 0.7 ± 0.8 | 0.7 ± 0.6 |
Range in frequency | 0–0.9 | 0.1–2.9 | 0–2.3 |
. | Control . | Revised ASRM Stage I-II . | Revised ASRM Stage III-IV . |
---|---|---|---|
Peripheral blood: | |||
CD4+CD25+FoxP3+ | |||
Treg cells | 5.5 ± 2.3 | 4.8 ± 2.9 | 5.2 ± 2.5 |
Range in frequency | 2.2–10.9 | 1.0–10.1 | 1.2–10.5 |
CD4+IL-17A+ | |||
Th17 cells | 0.5 ± 0.4 | 0.5 ± 0.4 | 0.3 ± 0.3 |
Range in frequency | 0–1.3 | 0–1.3 | 0–0.9 |
Peritoneal fluid: | |||
CD4+CD25+FoxP3+ | |||
Treg cells | 7.6 ± 2.8 | 6.9 ± 3.3 | 11.4 ± 6.8a |
Range in frequency | 3.2–14.9 | 1.4–11.4 | 2.6–24.5 |
CD4+IL-17A+ | |||
Th17 cells | 0.4 ± 0.3 | 0.7 ± 0.8 | 0.7 ± 0.6 |
Range in frequency | 0–0.9 | 0.1–2.9 | 0–2.3 |
Data given as mean % ± SD.
P < 0.05, stage III-IV endometriosis vs stage I-II endometriosis and control group.
Frequencies of Treg and Th17 Cells in the PB and PF of Women With and Without Endometriosis
. | Control . | Revised ASRM Stage I-II . | Revised ASRM Stage III-IV . |
---|---|---|---|
Peripheral blood: | |||
CD4+CD25+FoxP3+ | |||
Treg cells | 5.5 ± 2.3 | 4.8 ± 2.9 | 5.2 ± 2.5 |
Range in frequency | 2.2–10.9 | 1.0–10.1 | 1.2–10.5 |
CD4+IL-17A+ | |||
Th17 cells | 0.5 ± 0.4 | 0.5 ± 0.4 | 0.3 ± 0.3 |
Range in frequency | 0–1.3 | 0–1.3 | 0–0.9 |
Peritoneal fluid: | |||
CD4+CD25+FoxP3+ | |||
Treg cells | 7.6 ± 2.8 | 6.9 ± 3.3 | 11.4 ± 6.8a |
Range in frequency | 3.2–14.9 | 1.4–11.4 | 2.6–24.5 |
CD4+IL-17A+ | |||
Th17 cells | 0.4 ± 0.3 | 0.7 ± 0.8 | 0.7 ± 0.6 |
Range in frequency | 0–0.9 | 0.1–2.9 | 0–2.3 |
. | Control . | Revised ASRM Stage I-II . | Revised ASRM Stage III-IV . |
---|---|---|---|
Peripheral blood: | |||
CD4+CD25+FoxP3+ | |||
Treg cells | 5.5 ± 2.3 | 4.8 ± 2.9 | 5.2 ± 2.5 |
Range in frequency | 2.2–10.9 | 1.0–10.1 | 1.2–10.5 |
CD4+IL-17A+ | |||
Th17 cells | 0.5 ± 0.4 | 0.5 ± 0.4 | 0.3 ± 0.3 |
Range in frequency | 0–1.3 | 0–1.3 | 0–0.9 |
Peritoneal fluid: | |||
CD4+CD25+FoxP3+ | |||
Treg cells | 7.6 ± 2.8 | 6.9 ± 3.3 | 11.4 ± 6.8a |
Range in frequency | 3.2–14.9 | 1.4–11.4 | 2.6–24.5 |
CD4+IL-17A+ | |||
Th17 cells | 0.4 ± 0.3 | 0.7 ± 0.8 | 0.7 ± 0.6 |
Range in frequency | 0–0.9 | 0.1–2.9 | 0–2.3 |
Data given as mean % ± SD.
P < 0.05, stage III-IV endometriosis vs stage I-II endometriosis and control group.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.